Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 390.50
Bid: 391.50
Ask: 392.00
Change: 6.50 (1.69%)
Spread: 0.50 (0.128%)
Open: 391.00
High: 392.00
Low: 383.50
Prev. Close: 384.00
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

3 Nov 2020 07:00

RNS Number : 0019E
Chemring Group PLC
03 November 2020
 

FOR IMMEDIATE RELEASE 3 NOVEMBER 2020

 

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

 

CONTRACT AWARDS AND FINANCIAL YEAR-END UPDATE

 

Contract awards

Chemring is pleased to announce that in the final month of its financial year, its UK subsidiary, Chemring Countermeasures UK ("CCM UK"), has been awarded contracts worth £25.8m from the UK MOD to develop and supply naval countermeasures in support of the Royal Navy. Deliveries under these contracts will be made in FY21 through to FY23.

 

CCM UK has also received a £5.5m contract from the UK MOD to manufacture air countermeasures in support of the UK armed forces. Deliveries under this contract will be made during FY21 and FY22. All work under these contracts will be performed at CCM UK's Salisbury facility.

 

These countermeasures play a critical role in protecting air and naval forces from the threats posed by heat-seeking and radar-controlled missiles.

 

Year-end update

With continued positive momentum across the Group, trading for the year ending 31 October 2020 ended robustly. The Board's expectations are for adjusted operating profit to be at the top end of current market expectations.*

The continued focus on the management of working capital, cash generation and the reduction of intra-period net debt volatility has delivered positive results. Net debt at year end is now expected to be approximately £48m which includes £6.5m in respect of the first time adoption of IFRS16 (2019: £75.7m), driven by operating cash conversion of 110% of EBITDA, together with lower finance and tax payments.

The closing order book of £476m (2019: £449m) gives excellent visibility of FY21 revenue in both segments.

 

COVID-19 update

The health, safety and well-being of our people, their families, our customers and the communities in which we operate remain our first priority. All our facilities remain open, are operating in accordance with Government and State guidelines, and are applying stringent safeguards to minimise the spread of the virus. To date, our supply chain has remained robust and we have maintained deliveries of essential products and services to our customers.

FY20 results

Chemring's FY20 results are scheduled to be announced on 15 December 2020.

 

-ENDS-

 

* The current range of analyst expectations for adjusted operating profit for FY20 is £47m to £53m.

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 0203 128 8100

James Bavister

 

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTKKBBNABDDNDK
Date   Source Headline
13th Sep 20237:00 amRNSTransaction in Own Shares
12th Sep 20237:00 amRNSTrading update and contract wins
12th Sep 20237:00 amRNSTransaction in Own Shares
11th Sep 20237:00 amRNSTransaction in Own Shares
8th Sep 20237:00 amRNSTransaction in Own Shares
7th Sep 20237:00 amRNSTransaction in Own Shares
6th Sep 20237:00 amRNSTransaction in Own Shares
5th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 20237:00 amRNSTransaction in Own Shares
1st Sep 20231:04 pmRNSTotal Voting Rights
1st Sep 20237:00 amRNSTransaction in Own Shares
31st Aug 20237:00 amRNSTransaction in Own Shares
30th Aug 20237:00 amRNSTransaction in Own Shares
29th Aug 20237:00 amRNSTransaction in Own Shares
25th Aug 20237:00 amRNSTransaction in Own Shares
24th Aug 20237:00 amRNSTransaction in Own Shares
23rd Aug 20237:00 amRNSTransaction in Own Shares
22nd Aug 20237:00 amRNSTransaction in Own Shares
21st Aug 20237:00 amRNSTransaction in Own Shares
18th Aug 20237:00 amRNSTransaction in Own Shares
17th Aug 20237:00 amRNSTransaction in Own Shares
16th Aug 20237:00 amRNSTransaction in Own Shares
15th Aug 20237:00 amRNSTransaction in Own Shares
14th Aug 20237:00 amRNSTransaction in Own Shares
11th Aug 20237:00 amRNSTransaction in Own Shares
10th Aug 20237:00 amRNSTransaction in Own Shares
8th Aug 20237:00 amRNSUpdate on appointment of Chief Financial Officer
8th Aug 20237:00 amRNSTransaction in Own Shares
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20234:16 pmRNSDirector/PDMR Shareholding
4th Aug 20234:15 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 20239:26 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSShare buyback programme
3rd Jul 20237:00 amRNSDirector/PDMR Shareholding
21st Jun 20239:47 amRNSBlock listing Interim Review
13th Jun 20237:00 amRNSAppointment of non-executive director
6th Jun 20237:00 amRNSHalf year results to 30 April 2023
1st Jun 202310:28 amRNSTotal Voting Rights
24th May 20237:00 amRNSAppointment of Chief Financial Officer
2nd May 20232:51 pmRNSTotal Voting Rights
20th Apr 202312:02 pmRNSDirector Declaration
3rd Apr 20239:25 amRNSTotal Voting Rights
29th Mar 20237:00 amRNSContract Award
28th Mar 20233:29 pmRNSHolding(s) in Company
16th Mar 20234:23 pmRNSDoc re. Ordinary & Special Resolutions
15th Mar 20233:11 pmRNSResult of AGM
15th Mar 20237:00 amRNSAGM Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.